Eliciting Immune Responses Using Recombinant MVA Viruses Expressing HIV Env, Gag and Pol Anitgens
Methods for eliciting beneficial immune responses against HIV by administering to a subject a recombinant MVA virus expressing HIV env, gag, and pol antigens are described. The recombinant MVA is administered at least three times and, in certain embodiments, is administered to a patient that has not been treated with a DNA vaccine directed against HIV (i.e., has not been treated with a nucleic acid molecule encoding one or more HIV antigens). The methods can elicit production IgA antibodies directed against HIV in rectal secretions of a treated subject.
WO 2,011,047,031 [MORE INFO
ROBINSON HARRIET L [US]; MOSS BERNARD [US]; WYATT LINDA S [US]; AMARA RAMA R [US]
Type of Offer:
« More Biotech Patents